Abstract: Novel azabicyclic derivatives, processes for their preparation, pharmaceutical compositions containing them and their use as medicaments are disclosed.

Abstract: Mercapto amino acid derivatives of formula (I), wherein R is hydrogen, a salt-forming cation of a in vivo hydrolysable ester-forming group; R.sub.1 is selected from (a) and (b) in which A is a monocyclic aryl or heteroaryl ring and B is a monocyclic aryl, alicyclic or heterocyclic ring, C and D are independently --Z.sub.p --(CR.sub.8 CR.sub.9).sub.q -- or --(CR.sub.8 CR.sub.9).sub.q --Z.sub.p -- where p is 0 or 1, q is 0 to 3 provided that p+q in C is not 0, R.sub.8 and R.sub.9 are independently hydrogen or (C.sub.1-6)alkyl or together represent oxo and Z is O, NR.sub.10 or S(O).sub.x where R.sub.10 is hydrogen, (C.sub.1-6)alkyl or aryl(C.sub.1-6)alkyl and x is 0-2, and wherein C and D are linked ortho to one another on each of the rings A and B in formula (b); R.sub.2 is hydrogen, (C.sub.1-6)alkyl or aryl(C.sub.1-6)alkyl; R.sub.3 is hydrogen, (C.sub.1-6)alkyl optionally substituted by up to three halogen atoms, (C.sub.3-7)cycloalkyl, fused aryl(C.sub.3-7)cycloalkyl, (C.sub.3-7)cycloalkyl(C.sub.2-6)alkyl, (C.

Abstract: Novel phenyl derivatives which are useful as endothelin receptor antagonists.

Abstract: The invention provides hcd polypeptides and polynucleotides encoding Staphylococcus aureus 3-hydroxyacyl-CoA dehydrogenase (hcd) polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing hod polypeptides to screen for antibacterial compounds.

Abstract: The problem of formulating a dentifrice which is compatible with a bis-biguanide anti-bacterial agent, for instance chlorhexidine or alexidine, is solved by using a nonionic thickening agent; a nonionic surfactant; and an abrasive which is either a sparingly soluble salt, for instance calcium carbonate, (used in combination with an agent to suppress anion formation), or an essentially insoluble compound, for instance, a silica of low anion content, or a mixture thereof. Preferably, the composition has a flavor which is mainly aniseed, balanced by mints. Preferably during the preparation of a silica containing dentifrice, chlorhexidine and saccharin are added together at an early stage, prior to the addition of silica, to avoid the formation of lumps. Such dentifrices are useful in the prophylaxis and/or treatment of periodontal disease and caries.

Abstract: This invention concerns a tablet formulation which comprises a core containing a pharmaceutically active material, coated with a release retarding coating, and surrounded by a casing layer which includes a second pharmaceutically active material.

Abstract: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.

Abstract: Compounds of the general formula (I), and pharmaceutically acceptable salts thereof, ##STR1## in which X.sub.1 --(CH.sub.2).sub.x --X.sub.2 and the aromatic carbon atoms to which they are attached form a 5-7 membered ring,wherein:one of X.sub.1 and X.sub.2 is O, S or CH.sub.2 and the other is CH.sub.2 ;x is 1, 2 or 3;R.sub.1 is hydrogen, amino, halo, C.sub.1-6 alkyl, hydroxy or C.sub.1-6 alkoxy;R.sub.2 is hydrogen, halo, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, nitro, amino or C.sub.1-6 alkylthio;R.sub.3 is hydrogen, halo, C.sub.1-6 alkyl, C.sub.1-6 alkoxy or amino;R.sub.4 and R.sub.5 are independently hydrogen or C.sub.1-6 alkyl;Y is O or NH;Z is of sub-formula (a), (b) or (c): ##STR2## wherein n.sup.1 is 1, 2, 3 or 4; n.sup.2 is 1 or 2; n.sup.3 is 2, 3, 4 or 5;q is 0, 1, 2 or 3; p is 0, 0 or 2; m is 0, 1 or 2;R.sub.a is hydrogen or a lipophilic group, such as C.sub.1-12 alkyl or aralkyl; orR.sub.a is (CH.sub.2).sub.r --R.sub.10 wherein r is 2 or 3 and R.sub.10 is selected from cyano, hydroxyl, C.sub.

Abstract: Compounds of formula (3), and pharmaceutically acceptable salts and derivatives thereof, in which R.sup.1 is vinyl or ethyl; and R.sup.2 is a group R.sup.3, R.sup.4 CH.sub.2 --, or R.sup.5 R.sup.6 C.dbd.CH--; wherein each of R.sup.3 and R.sup.4 is an azabicyclic ring system or R.sup.5 and R.sup.6 together with the carbon atom to which they are attached form an azabicyclic ring system, are useful in the prevention and treatment of microbial infections.

Abstract: Mouthwash compositions are described comprising cetylpyridinium chloride and amidobetaine amphoteric surfactants of formula (I): RC(O)NH(CH.sub.2).sub.a N.sup.+ (R.sup.1)(R.sup.2)(CH.sub.2).sub.b CO.sub.2.sup.-, wherein R is C.sub.10-20 alkyl; R.sup.1 and R.sup.2 are independently C.sub.1-4 alkyl; a is an integer from 1 to 4; and b is an integer from 1 to 4.

Abstract: Invented is a novel pharmaceutical composition containing Paroxetine.

Abstract: This invention relates to substituted benzamido-heterocyclic compounds of general formula (I) having an alkoxy substituent at the C2 position of the benzamido group and various substituents at positions C4 and C5, being optionally substituted on the N atom of the heterocyclic system, and where the unsaturated ring of the heterocyclic system is a 5,6, 7 or 8-membered ring. Also to the use of these compounds as anticonvulsants in certain medical conditions, and to processes for making them.

Abstract: The present application is directed to the use of 5HT.sub.1B or 5HT.sub.1D receptor antagonists in the treatment of vascular diseases, in particular angina, Raynaud's syndrome, peripheral vascular syndrome or portal hypertension.

Abstract: Compounds of formula(I) where B is oxygen or sulphur, D is nitrogen, R.sup.6 and R.sup.7 forms a ring, m is 2, R is a substituted latam ring of formula (i) ##STR1## where p is 1, P is a substituted or unsubstituted bicyclic ring containing one or two heteroatoms or P is an unsbustituted or substituted 5- to 7-memebered saturated ring containing one or two heteroatoms; X, Y, Z, E, G, R.sup.3, R.sup.4, R.sup.5, R.sup.8, R.sup.9, and R.sup.10 are as defined in the specification.

Abstract: HGBAB90 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HGBAB90 polypeptides and polynucleotides in the design of protocols for the treatment of pulmonary emphysema, arthritis, multiple sclerosis, periodontal disease, cystic fibrosis, respiratory disease, thrombosis, cancer, cachexia, angina, glaucoma, inflamatory disorders, osteoporosis, cardiovascular disorders such as hypertension, atherosclerotic disorders such as cardiac infarction, and stroke, asthma, psoriasis, chronic neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's, demyelinating diseases, AIDS immune deficiency, disorders of photoreceptor degeneration, and lens cataract formation, organ transplant rejection, cataracts, restenosis, muscular dystrophy, renal failure, cerebral vasospasm, pancreatitis, and diabetic nephropathy, among others, and diagnostic assays for such conditions.

Abstract: Wnt-5b polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Wnt-5b polypeptides and polynucleotides in therapy, and diagnostic assays for such.

Abstract: A novel physical form of (E)-3-[6-[[(2,6-dichlorophenyl)-thio]methyl]-3-(2-phenylethoxy)-2-pyridiny l]-2-propenoic acid and its use in therapy is disclosed.

Abstract: Pharmaceutical formulations comprising ceftriaxone in combination with a penem of formula (I) in which R.sup.1 is hydrogen or an organic group; R.sup.2 is a ring system of formula (II), wherein R.sup.4 and R.sup.5 are hydrogen or one or more substituents; m is 2 or 3; p is 0, 1 or 2; R.sup.3 is hydrogen, a pharmaceutically acceptable salt-forming cation or a pharmaceutically acceptable in-vivo hydrolysable ester-forming group; and with a pharmaceutically acceptable carrier. The formulations have antibacterial activity, the compound of formula (I) acting as a .beta.-lactamase inhibitor.

Abstract: HTEGU07 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HTEGU07 polypeptides and polynucleotides in therapy, and diagnostic assays for such.

Abstract: Novel response regulator polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polynucleotides and polypeptides for the treatment of infection, particularly bacterial infections. Antagonists against such the polypeptides of the invention and their use as a therapeutic to treat infections, particularly bacterial infections are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to the presence the nucleic acid sequences and the polypeptides of the invention in a host. Also disclosed are diagnostic assays for detecting polynucleotides encoding response regulators and for detecting the polypeptide in a host.